Group One Trading
KALV

Group One Trading’s KalVista Pharmaceuticals KALV Stock Holding History

Group One Trading’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$1.61K – 8183
2025
Q4 		$1.61K Sell
100
-300
-75% -$3.97K ﹤0.01% 7615
2025
Q3 		$4.87K Buy
+400
New +$5.53K ﹤0.01% 7555
2025
Q1 		– Sell
-49,400
Closed -$418K – 7982
2024
Q4 		$418K Buy
49,400
+43,100
+684% +$446K ﹤0.01% 3325
2024
Q3 		$73K Buy
6,300
+600
+11% +$7.55K ﹤0.01% 4403
2024
Q2 		$67.1K Sell
5,700
-4,100
-42% -$47.8K ﹤0.01% 4286
2024
Q1 		$116K Buy
+9,800
New +$131K ﹤0.01% 4032
2021
Q4 		– Sell
-45,800
Closed -$799K – 8510
2021
Q3 		$799K Sell
45,800
-1,400
-3% -$28.4K ﹤0.01% 3657
2021
Q2 		$1.13M Buy
47,200
+25,700
+120% +$672K ﹤0.01% 3268
2021
Q1 		$552K Buy
21,500
+6,600
+44% +$173K ﹤0.01% 3923
2020
Q4 		$283K Buy
+14,900
New +$256K ﹤0.01% 3787

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Group One Trading's KALV Position: Q1 2026 in Review

Group One Trading sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 3,777 shares — an estimated $61K sold.

Group One Trading first reported a position in KALV in Q4 2020 and held it in 12 quarters. The position peaked at $171K in Q4 2024. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Group One Trading reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 3,777 KalVista Pharmaceuticals shares in Q1 2026, an estimated $61K.
  • Group One Trading first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 12 quarters.
  • Group One Trading's KalVista Pharmaceuticals position peaked at $171K in Q4 2024.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.